Download PDF
Thromb Haemost 1963; 09(03): 546-556
DOI: 10.1055/s-0038-1655007
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Purification of Activated Bovine Hageman Factor

John G. G Schoenmakers
1   Departments of Biochemistry and Internal Medicine School of Medicine and St. Radboud Hospital University of Nijmegen (The Netherlands)
,
R. M Kurstjens
1   Departments of Biochemistry and Internal Medicine School of Medicine and St. Radboud Hospital University of Nijmegen (The Netherlands)
,
C Haanen   *
1   Departments of Biochemistry and Internal Medicine School of Medicine and St. Radboud Hospital University of Nijmegen (The Netherlands)
,
F. Zilliken
1   Departments of Biochemistry and Internal Medicine School of Medicine and St. Radboud Hospital University of Nijmegen (The Netherlands)
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

    Permissions and Reprints

Summary

Activated Hageman Factor has been purified 3000 to 5000 fold from citrated bovine plasma as measured in a thoroughly devised assay procedure. The steps of purification include adsorption on aluminium hydroxide gel, glass, diethyl- aminoethyl cellulose and Sephadex G-200. A fractionation according to Cohn between step 2 and 3 renders the factor more stable for further purification. The purified preparations corrected the clotting defect in human plasma with Hageman trait. The most purified fractions were devoid of plasma thromboplastin antecedent (PTA), other clotting factors.

* This study was supported in part by the Organisation for Health Research, T N O, the Netherlands.


 

  • References

  • 1 Ratnoff O. D, Rosenblum J. M. Role of Hageman factor in the initiation of clotting by glass: evidence that glass frees Hageman factor from inhibition. Amer. J. Med. 25: 160 1958;
    CrossrefPubMedGoogle Scholar
  • 2 Vroman L. Surface contact and thromboplastin formation. Thesis: University of Utrecht; 1958
    Google Scholar
  • 3 Johnston C. L, Ferguson J. H, O’Hanlon F. A. Surface activation of plasma clotting: a function of Hageman factor. Proc. Soc. exp. Biol. (N. Y) 99: 197 1958;
    CrossrefPubMedGoogle Scholar
  • 4 Soulier J. P, Wartelle O, Ménaché D. Hageman trait and PTA deficiency: the role of contact of blood with glass. Brit. J. Haemat. 05: 121 1959;
    CrossrefPubMedGoogle Scholar
  • 5 Waaler B. A. Contact activation in the intrinsic blood clotting system. Studies on a plasma product formed on contact with glass and similar surfaces. Scand. J. clin. Lab. Invest 11 Suppl. 37 1959;
    CrossrefPubMedGoogle Scholar
  • 6 Margolis J. Activation of plasma by contact with glass: evidence for a common reaction which releases plasma kinin and initiates coagulation. J. Physiol., Lond 144: 1 1958;
    PubMedGoogle Scholar
  • 7 Hardisty R. M, Margolis J. The role of Hageman factor in the initiation of blood coagulation. Brit. J. Haemat. 05: 203 1959;
    CrossrefPubMedGoogle Scholar
  • 8 Ratnoff O. D, Davie E. W, Mallett D. L. Studies on the action of Hageman factor: Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J. clin. Invest 40: 813 1961;
    PubMedGoogle Scholar
  • 9 Schiffman S, Rapaport S. I, Ware A. G, Mehl J. W. Separation of PTA and HF from human plasma. Proc. Soc. exp. Biol. (N. Y) 105: 453 1960;
    CrossrefPubMedGoogle Scholar
  • 10 Haanen C, Hommes F, Benraad H, Morselt G. A Case of Hageman- Factor Deficiency and a Method to Purify the Factor. Thrombos. Diathes. haemorrh. (Stuttg) 05: 201 1961;
    PubMedGoogle Scholar
  • 11 Didisheim P. Purification of Hageman factor. Fed. Proc. 20. March 1961
    PubMedGoogle Scholar
  • 12 Ratnoff O. D, Davie E. W. The Purification of Activated Hageman Factor (Activated Factor XII. Biochemistry. 01: 967 1962;
    CrossrefPubMedGoogle Scholar
  • 13 Rapaport S. I, Schiffman S, Patch M. J, Ware A. G. A simple, specific one-stage assay for Plasma Thromboplastin Antecedent activity. J. Lab. clin. Med. 57: 771 1961;
    PubMedGoogle Scholar
  • 14 Alkjaersig N, Fletcher A. P, Sherry S. The mechanism of clot dissolution by plasmin. J. clin. Invest 38: 1086 1959;
    CrossrefPubMedGoogle Scholar
  • 15 Astrup T, Miillertz S. The fibrin plate method for estimating fibrinolytic activity. Arch. Biochem. 40: 346 1952;
    CrossrefPubMedGoogle Scholar
  • 16 von Kaulla K. N, Schultz R. L. Methods for the evaluation of human fibrinolysis. Amer. J. clin. Path. 29: 104 1958;
    PubMedGoogle Scholar
  • 17 Iatridis S. G, Ferguson J. H. Effect of Surface and Hageman Factor on the Endogenous or Spontaneous Activation of the Fibrinolytic System. Thrombos. Diathes. haemorrh. (Stuttg) 06: 411 1961;
    PubMedGoogle Scholar
  • 18 Christensen L. R. Methods for measuring activity of components of streptococcal fibrinolytic system and streptococcal desoxyribonuclease. J. clin. Invest 28: 163 1949;
    CrossrefPubMedGoogle Scholar
  • 19 Lowry O. H, Rosebrough N. J, Farr A. L, Randall R. J. Protein measurement with the Folin Phenol reagent. J. biol. Chem. 193: 265 1951;
    PubMedGoogle Scholar
  • 20 Iatridis S. G, Ferguson J. H. Active Hageman Factor: J. clin. Invest 41: 1277 1962;
    CrossrefPubMedGoogle Scholar
  • 21 Cohn E. J, Strong L. T, Hughes W. L, Mulford D. J, Ashworth J. N, Melin M, Taylor H. L. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J. Amer. chem. Soc. 68: 459 1946;
    PubMedGoogle Scholar
  • 22 Smithies O. An Improved Procedure for Starch-gel Electrophoresis: Further Variations in the Serum Proteins of Normal Individuals. Biochem. J. 71: 585 1959;
    CrossrefPubMedGoogle Scholar
  • 23 Davis B. J, Ornstein L. Disc. Electrophoresis. Preprinted by Destillation Products Industries. Rochester, USA.:
    Google Scholar
  • 24 Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (factor VII. Act. haemat. (Basel) 06: 1 1951;
    PubMedGoogle Scholar
  • 25 Owren P. A, Aas K. The control of dicoumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest. 03: 201 1951;
    CrossrefPubMedGoogle Scholar
  • 26 Niewiarowski S, Prou-Wartèlle O. Rôle du facteur contact (facteur Hageman) dans la fibrinolyse. Thrombos. Diathes. haemorrh. (Stuttg) 03: 593 1959;
    PubMedGoogle Scholar
  • 27 Gelotte B, Flodin P, Killander J. Fractionation of Human Plasma by Gel Filtration and Zone Electrophoresis or Ion-Exchange Chromatography. Arch. Biochem. Suppl. 01: 319 1962;
    PubMedGoogle Scholar